Reaction

Keratitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,980 reports · 88 co-occurring drugs

As of the last recalculation, Keratitis appears in 2,980 FAERS reports alongside 88 co-occurring drug terms. The strongest observed disproportionality signal is PREDNISOLONE ACETATE (PRR 31.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Prednisolone Acetate	46	31.5	31.7
Moxifloxacin Hydrochloride	59	20.7	20.8
Cimetidine	26	19.0	19.1
Tobramycin Solution	26	15.2	15.3
Panitumumab	33	14.9	14.9
Tobramycin Sulfate	26	14.8	14.8
Brinzolamide	18	14.6	14.6
Tobramycin	48	14.2	14.2
Carboxymethylcellulose Sodium	18	13.5	13.5
Chlorhexidine Gluconate	16	12.3	12.3
Methylprednisolone Acetate	13	11.4	11.4
Moxifloxacin	21	10.5	10.5
Naproxen Sodium Tablet, Coated	20	10.4	10.4
Naproxen Sodium, Coated Tablets	20	10.4	10.4
Naproxen Sodium 220Mg	20	10.4	10.4
Lifitegrast	22	9.5	9.5
Dorzolamide Hydrochloride And Timolol Maleate	10	8.9	8.9
Brimonidine Tartrate	22	8.7	8.7
Fosaprepitant Dimeglumine	17	8.7	8.7
Faricimab	10	8.6	8.7
Pertuzumab	31	8.0	8.0
Timolol	13	7.5	7.6
Mometasone	19	7.3	7.3
Aprepitant	19	7.2	7.2
Gentamicin Sulfate	16	7.1	7.1
Gentamicin	13	7.0	7.0
Cenegermin-Bkbj	12	7.0	7.0
Fam-Trastuzumab Deruxtecan-Nxki	10	6.9	7.0
Ganciclovir	10	6.8	6.8
Telmisartan	17	6.7	6.7
Irbesartan	42	6.6	6.7
Bimatoprost	27	6.6	6.6
Aflibercept	29	6.5	6.6
Erythromycin	17	6.4	6.4
Latanoprost	45	6.3	6.3
Pemetrexed Disodium	34	6.3	6.3
Adalimumab-Fkjp	41	6.3	6.3
Ranibizumab	23	6.1	6.1
Tretinoin	7	6.0	6.0
Cyclosporine	92	5.9	5.9
Pemetrexed	18	5.9	5.9
Adalimumab-Aaty	39	5.8	5.8
Metformin Hydrochloride Tablets	47	5.8	5.8
Metformin Hydrochloride Extended-Release Tablets	47	5.8	5.8
Metformin Hydrochloride Tablet	47	5.8	5.8
Metformin Hydrochloride	47	5.6	5.6
Trastuzumab	54	5.6	5.6
Febuxostat Tablets 40 Mg	8	5.5	5.5
Febuxostat Tablets 80 Mg	8	5.5	5.5
Loperamide Hydrochloride Oral	8	5.5	5.5
Ganciclovir Sodium	8	5.3	5.3
Hydroxychloroquine	55	5.2	5.2
Adalimumab-Adaz	39	5.2	5.2
Anti-Thymocyte Globulin (Rabbit)	6	5.2	5.2
Diclofenac Sodium 1%	24	4.7	4.7
Diclofenac Sodium Topical	24	4.7	4.7
Diclofenac Sodium Topical Gel, 1%	24	4.7	4.7
Gefitinib	6	4.6	4.7
Cetuximab	20	4.5	4.5
Dupilumab	284	4.4	4.4
Imatinib	11	4.4	4.4
Loperamide Hcl	8	4.4	4.4
Osimertinib	19	4.2	4.2
Ado-Trastuzumab Emtansine	5	4.1	4.1
Erlotinib Hydrochloride	7	3.9	3.9
Abatacept	74	3.8	3.8
Golimumab	45	3.7	3.7
Erlotinib	5	3.6	3.6
Vemurafenib	6	3.5	3.5
Pembrolizumab	50	3.4	3.4
Dabrafenib	10	3.3	3.3
Paclitaxel	46	3.3	3.3
Paclitaxel (Aibumin-Bound)	38	3.3	3.3
Travoprost	4	3.2	3.2
Levocetirizine Dihydrochloride	11	3.2	3.2
Capecitabine	41	3.2	3.2
Bosutinib	4	3.1	3.1
Atezolizumab	17	3.1	3.1
Nivolumab	41	3.0	3.0
Trametinib	10	2.9	2.9
Carfilzomib	10	2.5	2.5
Ipilimumab	15	2.4	2.4
Durvalumab	7	2.4	2.4
Botulinum Toxin Type A	4	2.3	2.3
Isotretinoin	15	2.1	2.1
Pomalidomide	26	1.8	1.8
Salicylic Acid	3	0.4	0.4
Adapalene	4	0.2	0.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.